Brean Capital Buy Gentium (NASDAQ: GENT) price target of $60.00 (from $38.00). Thhe change follows EMA approval of defibrotide.
This article: 109 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE